<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03229200</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1145-LT</org_study_id>
    <nct_id>NCT03229200</nct_id>
  </id_info>
  <brief_title>Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.</brief_title>
  <official_title>Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics Switzerland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics Switzerland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, prospective treatment protocol that provides continued access to
      ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from
      treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying
      disease within their region.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, open-label, prospective treatment protocol that provides continued access to
      ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from
      treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying
      disease within their region.

      Subjects enrolled in this treatment protocol will receive oral continuous dosing with
      ibrutinib at the same dose and schedule they were receiving at the end of the respective
      parent study. Treatment may be continued as long as the subjects continue to derive benefit
      from treatment with ibrutinib until such time that ibrutinib becomes commercially available
      for the indication of the parent study.

      Clinical evaluations (including safety assessments) will be performed per local standard of
      care for each disease that was studied in the parent protocol. At each visit, all ongoing and
      new onset non-serious AEs leading to dose reduction or discontinuation, serious adverse
      events (SAEs), adverse events of special interest (AESI), pregnancy events, other
      malignancies, and special reporting situations will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2017</start_date>
  <completion_date type="Anticipated">July 2, 2027</completion_date>
  <primary_completion_date type="Anticipated">July 2, 2027</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective of protocol PCYC-1145-LT is to provide long-term access to ibrutinib for subjects who meet the selection criteria.</measure>
    <time_frame>The duration will be 3 years and will be re-evaluated.</time_frame>
    <description>Assessment of percentage of patients rolling over from each parent study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the drug safety profile by collecting long-term safety data for ibrutinib.</measure>
    <time_frame>Up to 3 years and will be re-evaluated.</time_frame>
    <description>Number of participants with treatment emergent serious adverse events and adverse events of special interest as assessed by CTCAE v4.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Leukemia, B-cell</condition>
  <condition>Graft Vs Host Disease</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Ibrutinib, once daily until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.</description>
    <arm_group_label>Ibrutinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must currently be participating in an ibrutinib clinical trial, deriving
             clinical benefit from treatment with ibrutinib in the opinion of the treating
             physician and do not have access to commercial ibrutinib within their region.

          -  Ongoing continuous treatment with ibrutinib.

          -  Subject must have completed all assessments in their parent protocol and want to
             continue treatment with ibrutinib.

          -  Subject has provided informed consent.

          -  Male and female subjects of reproductive potential who agree to use both a highly
             effective method of birth control and a barrier method during the period of therapy
             and for 90 days after the last dose of drug.

        Exclusion Criteria:

          -  Meeting any requirement in the parent protocol to permanently discontinue ibrutinib
             treatment.

          -  Any condition or situation which, in the opinion of the treating physician, may
             interfere significantly with a subject's participation in the protocol.

          -  Female subjects who are pregnant, or breastfeeding, or planning to become pregnant.
             Male subjects who plan to father a child while enrolled in this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard Hauns, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics LLC.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Viktor Fedorov, MD</last_name>
    <phone>+41 52 556 0800</phone>
    <email>vfedorov@ch.pcyc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy &amp; Patricia Disney Family Cancer Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Mena</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven DeVos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Rosenblatt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuo Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonali Smith</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tycel Phillips</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nalini Janakiraman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TRIO - Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169-3321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regan Holdridge</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center, Hackensack UMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Goy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morton Coleman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline C Barrientos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-6007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia Palomba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Ohio Oncology/Hematology Inc., DBA The Mark H. Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Knapp</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William C Ehmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jakub Svoboda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Fowler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>START - South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drew Rasco</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herv√© Tilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2017</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

